For dividend growth investors seeking a blend of stability, scalability, and consistent income, this healthcare stock delivers exactly that. Operating across diagnostics, nutrition, medical devices, and pharmaceuticals, the company benefits from a globally diversified footprint and has built a reputation for uninterrupted dividend growth spanning over five decades. Most notably, its 3-year dividend compound annual growth rate (CAGR) stands at 7%—comfortably within the top 40% of all dividend-paying stocks—signaling both management’s commitment to capital return and the company’s ability to generate sustainable cash flows.
The healthcare and medical devices sectors continue to experience strong tailwinds from demographic shifts, such as aging populations and increased chronic disease management needs. This stock is well-positioned to capitalize on these trends through innovations in areas like glucose monitoring and cardiovascular care, as well as growing demand in emerging markets. While risks remain—such as exposure to global currency fluctuations and soft spots in the diagnostics segment—its strong financials, low debt, and broad product diversification help balance out these headwinds. Investors looking to understand how this company has maintained a “Hold” recommendation with top-tier rankings in sentiment, safety, and investability will find valuable insights in our full analysis.
Since the most recent earnings call on April 15, 2025, investor confidence appears to have modestly strengthened. The stock has climbed 4.18%, while analyst sales and EBITDA estimates have edged up by 0.84% and 0.59%, respectively. Interestingly, EPS estimates saw a slight dip of 0.53%, signaling a more cautious profit outlook.
For a deeper dive into what these estimate shifts mean for long-term dividend growth potential—and why this stock remains a core holding in our Dividend Growth Portfolio—read the complete article.
